Abiraterone not recommended for newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer
The cost-effectiveness estimates of either abiraterone in combination compared with ADT alone or with docetaxel plus ADT for the whole population are higher than what NICE considers cost effective, according to final guidance.
Published